Index

Note: Numbers in bold refer to Figures and Tables.

ABCDE resuscitation principles 109
abdominal compartment syndrome 123
abdominal injury, whole-body CT scanning 117
abdominal sonography, ultrasound 114
activated partial thromboplastin time 61–2
activated protein C (APC), recombinant (drotrecogin alfa) 58, 69, 151–5
absolute/relative contraindications 155
anti-inflammatory properties 152–3
clinical studies 153–4
future developments 156
practical considerations 155
adipose tissue, and insulin therapy 188
aerobic Gram-negative bacilli (AGNB) 161–2
alcohol dependence
life-time prevalence 197
withdrawal prophylaxis and treatment 205
aldosterone antagonists, chronic heart failure 92
amphetamine 206
anaesthetic agents
inhalational vs i.v. 80
interaction with ischaemic injury 78
and myocardial protection 77–88
potential harmful mechanisms 85–6
reperfusion injury 78–80
anaesthetic-induced cardioprotection 85–6
see also substance use disorders
analgesia, chest trauma 119–120
angina, and preconditioning 81
angiotensin converting enzyme (ACE) inhibitors 19, 20
chronic heart failure 91
angiotensin II receptor antagonists, chronic heart failure 92
anticoagulants 69–70
antidepressants 26
antimicrobials, enteral/parenteral 164
aorta, traumatic rupture 107
apolipoprotein E 20
ARDS, post-traumatic 118
arterial blood pressure, variations 143–6
ATP-binding cassette (ABC) 94
automatic implantable cardioverter defibrillators (AICDs) 92
azathioprine 4
barbiturates
and anaesthesia 206
blockade of potassium channel 85
bendrofluazide, heart failure 92
benzodiazepines 206
β-2 adrenergic receptor 20
beta-blockers, chronic heart failure 91–2
bioinformatics 2, 21–2
bisoprolol, chronic heart failure 91–2
bleeding disorders, recombinant factor VIIa 70–1
blood pressure, ACE inhibitors 19
blunt chest trauma see chest trauma
bovine adrenal medulla peptide-22 (BAM-22) 44
brain natriuretic peptide 91
human recombinant (nesiritide) 96
bronchial wounds 106
bumetamide, heart failure 92
buprenorphine 45
butorphanol 45
C-reactive protein, lipid metabolism 182
calcium antagonists, and heart failure 93–2
cAMP 40, 197
cAMP-response-element-binding proteins (CREBs) 40, 43, 197
candesartan 92
cannabis (marijuana) 207
cardiac markers, assays 115–6
cardiac resynchronization therapy (CRT) 94
cardiactransplantation 95
cardioprotection see myocardial protection
cardiopulmonary resuscitation 119
 cardiopulmonary 119
cardiopulmonary 119
cardiopulmonary failure 104
cardiopulmonary injuries 107
haemodynamic care 122–3
carrier proteins (membrane transporters) 15–18
carvedilol, chronic heart failure 91-2
cDNA, expressed sequence tags (ESTs) 21
cefotaxime 165
cervical spine, standard X-rays 110
chest trauma 103–31
assessment and diagnosis 108–16
abdominal sonography 114
Organ Injury Scaling 103, 104
physical examination 109
secondary assessment and surgery prerequisites 117–9
sonographic assessment 110–15
standard X-rays 109–10
transcranial Doppler 114–5
ultrasound-guided vascular access 115
whole-body CT scanning 117–8
cardiopulmonary complications 107
chest wall injuries 104–6
secondary surgery 118–9
therapeutic strategy 119–23
analgesia 119–20
cardiopulmonary resuscitation 119
cardiovascular care 122–3
deep venous thrombosis prevention 123
haemodynamic stability 120
intercostal drainage 121
mechanical ventilation 121–22
pain management 120
post-traumatic goal-directed therapy 122–3
regional analgesia 120
respiratory care 121–2
systemic analgesia 119
thoracic aorta rupture 107
troponin concentration 116
coagulation 55–74
acquired disorders 67–70
antiocoagulants 69–70
dilutional coagulopathy 68–70
disseminated intravascular coagulation (DIC) 69
factor deficiencies 71
intractable haemorrhage 67–8
bleeding disorders 70–1
effects of critical illness 182–4
Index

haemostasis, normal 56–62
hereditary disorders 63–5
of fibrinolysis 66
of haemostasis 62–7
importance in sepsis 151–2
model 59
tests of coagulation 61–2
thrombotic disorders 66–7
cocaine 206
codeine, CYP2D6 phase-I metabolism 4, 8–9
cor pulmonale 133–4
critical illness see intensive care and critical illness
CT see whole-body CT scanning
CYP2A6, phase-I metabolism, and smoking 12–13
CYP2C9, warfarin 9–12
CYP2C19, proton-pump inhibitors 12
CYP2D6 locus, debrisoquine: 4-hydroxydebrisoquine ratio 9
CYP450 enzymes
microarrays 24
phase-I metabolism 7–13
cystic fibrosis, CFTR 17
debri sor quine: 4-hydroxydebrisoquine ratio, CYP2D6 locus 9
deductive genomics 24
deep venous thrombosis, prevention in chest trauma 123
defibrillators, AICDs 94
depression, drug targets 17–18
desflurane, interaction with ischaemic injury 78, 80
desmopressin (DDAVP) 64, 71
diabetes mellitus
glycaemic control, improved outcomes with tight control 179–82
metabolic management in intensive care 186–7
and myocardial infarction 181
renal failure 182
sensory neuropathy 182–3
diaphragmatic injury 105–106
digestive tract see selective decontamination
digoxin, heart failure 93
dilutional coagulopathy 68–70
disseminated intravascular coagulation (DIC) 69
diuretics, heart failure 92
DNA microarrays, gene expression studies 22–4
dobutamine, heart failure 96
dopamine, heart failure 96
dopamine receptor 20
Doppler, transcranial 114–5
drotrecogin alfa see activated protein C
drug development 21–4
bioinformatics 21–2
databases 22
definitions 23
microarrays and gene expression studies 22–4
recent trends 24
drug metabolizing enzymes (DMEs), 7–8
drug response variability 1–33
carrier proteins (membrane transporters) 15–18
ethical and legal issues 25
and future health care 25–6
interindividual variability 4–8
drug metabolizing enzymes (DMEs) 7–8
mutations 4–5
pharmacokinetic variability 5–8
phase-I P450 enzymes 8–9
see also pharmacogenomics
ECG recording 115–6
echocardiography 114, 136
Edinger–Westphal nuclei 46
endorphins 44
dermorphins 43
endothelial adhesion factors 152
enflurane, interaction with ischaemic injury 77, 78
enoximone, heart failure 96
eplerenone 92
evidence-based medicine (EBM), ICU recommendations 166
expressed sequence tags (ESTs) 21
factor deficiencies
coagulation disorders 64–5, 70 recombinant VIIa 71
VIII and IX 64–7 factor V Leiden 67
fentanyl, structure 35–7
toxifenodamine 16
fibrin, generation in haemostasis 56–60
fibrinogen, hypofibrinogenaemia 69
fibrinogen degradation products 60–1
fibrinolysis 60–1
flail chest 104
fluid responsiveness see functional haemodynamic monitoring
frameshift mutation 5
Frank–Starling relationship 134–137, 140
frusemide, heart failure 92
functional haemodynamic monitoring 133–50
algorithm, treatment of instability 147
left ventricular stroke volume variations 142–143
positive-pressure ventilation 138–141
protocol 147
right atrial pressure variations 142
spontaneous variation in BP 136–138
static measures of cardiovascular status 134–136
systemic arterial blood pressure variations 143–146
systolic pressure and pulse pressure variations 143–146
usefulness 141–143
velocity and flow variations 146
G-protein-coupled receptor kinases (GRKs) 42
G-protein-coupled receptors 38–40
SNSRs 44
G-proteins, interactions with opioids 41
gene chips see microarrays
gene expression analysis 22–4
gene therapy, ethical and legal issues 25
genetic markers, SNPs 18–19
genomics defined 23
see also pharmacogenomics
Glanzmann’s thrombasthenia 63–4
glibenclamide, blockade of potassium channel 85
gluconeogenesis,
phosphoenolpyruvate carboxykinase (PEPCK) 187
glucose 6-phosphate dehydrogenase deficiency 3
glucose, regulation see glycaemic control
Glucono-δ-lactone, Phase-II metabolism 14
glycaemic control 177–194
diabetes
improved outcomes with tight control 180–182
metabolic management during critical illness 186–187
hyper-, normo- or hypocaloric nutrition 185–186
hyperglycaemia, defined 177–178
hyperglycaemia in critical illness 182–184
associated neuropathy 182–183
associated renal failure 182
historical rationale for management 178–179
immune system impairment and risk of infection 183–184
impairment of lipid metabolism 184
improvement of outcome with normoglycaemia 178–180
infections 180
insulin therapy 187–189
effects on inflammation and coagulation 184–186
trauma/critical illness 177–178

haemodynamic monitoring see functional haemodynamic monitoring

haemophilia 64–5
acquired 70
haemorrhage, intractable, in hospital practice 67–8

haemostasis 56–62
fibrin generation 56–60
fibrinolysis 60–1
hereditary disorders 
clinical features 63–4
treatment 64
inhibition of coagulation after cloting 58–60
primary haemostasis 56

haemothorax 107, 113

drainage 121
halothane, and reperfusion injury 78

heart failure 89–95
aetiology 89–90
epidemiology 88
investigations 90–91
pathophysiology 90

heart failure, acute
non-invasive ventilation 97
therapy, recent advances 96–97

heart failure, chronic

cardiac resynchronization therapy (CRT) 94

cardiac transplantation 95
device therapy 94–5
disease-modifying therapy 91–92
left ventricular assist devices (LVADs) 94–95

lifestyle modification 94
non-pharmacological intervention 94

pharmacological therapy 91–93

surgical options 95

symptomatic therapy 92

heparins 69–70

heroin and other opioids 200–201
continuation of opioid maintenance programmes 202
opioid antagonists 204

transient perioperative administration of methadone 202

withdrawal prophylaxis and treatment 202

HIV infection and AIDS, PGP polymorphisms and therapy enhancement 16

5-HTT gene, serotonin transporter 18

hydralazine, chronic heart failure 92

hydroxytryptamine receptor 20

hyperglycaemia see glycaemic control

hypoglycaemia, effects and complications 186–187

hypoglycaemic agents, blockade of cardioprotection 85

hypoprothrombinaemia, acquired 70

inflammation, effects of critical illness 184

insulin therapy

and adipose tissue 188
effects on inflammation and coagulation 184

endotoxin scavenging 184
see also glycaemic control

insulin-like growth factor binding protein-1 (IGFBP-1) 187

intensive care/critical illness

diabetes 180

improved outcomes with tight control 180

metabolic management 186
evidence-based medicine (EBM) 166

glycaemic control 177

hyper-, normo- or hypocaloric nutrition 184
intensive care/critical illness (cont’d)
impairment of lipid metabolism 184
infections 161
endogenous/exogenous PPMs 161
normal/abnormal PPMs 160
inflammation and coagulation 184
interventions that reduce mortality 166
neuropathy 181–182
renal failure 182
selective decontamination of digestive tract (SDD) 161
see also glycaemic control
intercostal drainage 121
intercostal nerve block 120
ischaemia see myocardial protection
isoflurane, interaction with ischaemic injury 78
ketamine, blockade of potassium channel 85
left ventricular assist devices (LVADs) 94
left ventricular stroke volume, variations 142
left ventricular systolic dysfunction 89–101
see also heart failure
leucotriene receptor 20
levosimendan 96–97
lipid metabolism, impairment in critical illness 184
5-lipoxygenase (ALOX5) gene 19, 20
long QT syndrome 19
lung contusion 104, 117
lysergic acid diethylamine (LSD) 207–208
mediastinum, standard X-rays 109–110
α-melanocyte stimulating hormone (MSH) 44
membrane transport proteins 15–18
single nucleotide polymorphisms 4–5, 17
meningococcal sepsis
PAI-1 levels 69
protein C 69, 151
mercaptopurine 4
methadone, structure 36–37
metolazone, heart failure 90, 92
metoprolol, chronic heart failure 89–91
microarrays, and gene expression studies 22–4
midazolam, effect on potassium channel 85
milrinone, heart failure 96
mitogen-activated protein kinases (MAPKs) 85
monocyte chemoattractant protein-1 (MCP-1) 153
morphine
binding 47–48
clinical features 63–64
epidural infusion 120
glucuronides 46
structure–activity 35–7
MRSA, ICU infections 162–169
multidrug resistance gene (MDR1) 15–16
multiple organ failure 122
myocardial contusion 107, 114
myocardial infarction, and diabetes 180, 181
myocardial protection 77–88
blockade by anaesthetics and oral hypoglycaemic agents 85
opioid-induced 84
preconditioning 78–83
N-acetyltransferase (NAT) NAT1 and NAT2 15
phase-II metabolism 13
N-methyl-D aspartate (NMDA) receptors 42, 43
nalbuphine 45
nalorphine, structure 36–37
naloxone 35–7, 43, 48
naltrexone 45
nesiritide, heart failure 96
neuropathy, and insulin therapy in critical illness 182–3
nitrates
acute heart failure 92
chronic heart failure 92
volatile (substance use) 205
NMDA receptor antagonists 43
nociceptin 38
NSAIDs, and heart failure 93
nutrition, hyper-, normo- or hypocalorific nutrition 185–186
oesophageal trauma 107
oestrogen receptor alpha 20
opioid receptor antagonists 37
opioid receptors 37–43, 20
molecular cloning 37–8
ORL-1 38
peripheral receptors and inflammation 47–8
SNPs 18
structural features 38–40
topology 39
trafficking 42–3
types 37–8
opioids 35–53
peripheral sites 46–9
structure–activity 35–7
substance use disorders (SUD) and anaesthesia 200–204
supraspinal and spinal sites 45–6
Organ Injury Scaling 104, 105
 orphanin FQ 38
P450 enzymes, phase-I metabolism 7–13, 10–11
P-glycoprotein (PGP), substrates (drugs) 16
P-glycoprotein (PGP) multidrug transporter 15–16
pain management, chest trauma 120
paravertebral block 120
pentazocine 45
pharmacodynamic variability, receptors 18–20
pharmacogenetics defined 2, 23
history 2–3, 4
pharmacogenomics 1–33
carrier proteins (membrane transporters) 15–18
deductive genomics 24
defined 23
drug development 21–4
databases 22
erthic and legal issues 25
pharmacodynamic variability 18–20
pharmacokinetic variability 5–8
phase-I metabolism 8–13
CYP2A6 (smoking) 12–13
CYP2C9 (warfarin) 9–12
CYP2C19 (proton-pump inhibitors) 12
CYP2D6 (codeine, tramadol) 4, 8–9
CYP2E1 (volatile anaesthetic agents) 13
CYP P450 enzymes 7–8
phase-II metabolism 13–15
glucuronidation 14
N-acetyl transferase (NAT) 15
pharmacogenomics (cont’d)
phase-II metabolism (cont’d)
thiopurine S-methyl transferase (TPMT) 14–15
web sites 32–3
see also drug response, variability
pharmacokinetic variability 5–8
pharmacophylogenomics, defined 23
pharmacoproteomics, defined 23
phencyclidine 205–6
phosphoenolpyruvate carboxykinase (PEPCK), gluconeogenesis 187
phylogenomics 21
defined 23
plasminogen activation inhibitor-1 (PAI-1) 66, 71
platelet activating factor (PAF) 151
platelet function analyser (PFA100) 62, 64
platelets, activation and aggregation 56–7
pleural sonography 111–12
pneumothorax 104, 110
drainage 119
polymyxin E/tobramycin 164–6
potassium voltage-gated channel 20
blocked by barbiturates and ketamine 85
preconditioning 78–83
angina and 81
and myocardial protection 78–83
pharmacological, with anaesthetic agents 80–3
preload indicators, receiver–operator characteristic 145
preload responsiveness 133–4
pro-dynorphin (PDYN) 38, 43–4
pro-enkephalin (PENK) 44, 48
pro-opiomelanocortin (POMC) 44, 48
propofol
effect on potassium channel 85
and myocardial function 78
protease-activated receptors (PARs) 152
protein C, activated protein C (APC) 58, 69, 151–5
protein kinases, A and C. 42
proteomics, defined 23
prothrombin, hypoprothrombaemia 70
prothrombin complex concentrates 70
prothrombin time 61–2
proton-pump inhibitors, phase-I metabolism CYP2C19 12
pulmonary injuries 106–7, 7
pulmonary vascular resistance (PVR) 139
pulsus paradoxus 136–8, 3
reverse 138
regional analgesia 120
renal failure, and insulin therapy in critical illness 180
reperfusion injury
definition 78
interaction of anaesthetics 8, 80–1
mechanisms and clinical manifestations 8–9
replacement therapy
cryoprecipitate 69, 71
FFP 68, 70
platelets 68, 70
prothrombin complex concentrates 70
respiratory care, chest trauma 121–2
resuscitation
ABCD principles 109
secondary, AMPLE 109
reverse genomics 24
defined 23
right atrial pressure, variations 142
RNA, small interfering (siRNA) 24
ryanodine receptor (RYR1) 18–19, 20
scapular fractures 104–5
selective decontamination of digestive tract (SDD) 161–9
evidence 5–6
future aspects 168–9
infection in intensive care unit 161–3
protocol 164–5
questions on use 166–8
selective serotonin reuptake inhibitors (SSRIs) 18
sensory neuron-specific G-protein-coupled receptor (SNSR) 44
sensory neuropathy, in diabetes 182–3
sepsis 151–6
APC (activated protein C) 151–5
importance in coagulation 151–2
pathogenesis 151–5
serotonin receptor 5-HT_4 46
serotonin transporter, 5-HTT gene 18
sevoflurane
interaction with ischaemic injury 78, 79, 80
cardioprotection 84
signal transducer and activator of transcription factors (STAT) 47
signal transduction, opioids 40–3
single nucleotide polymorphisms (SNPs) 4–5, 17
generic markers 18–19, 20
slow acetylators 3
smoking, phase-I metabolism,
CYP2A6 12–13
spironolactone 90
standard X-rays 109–10
Staphylococcus aureus (methicillin-resistant, MRSA) 161–168
statins, heart failure 93
sternal fractures 104–105
streptokinase 167
substance use disorders (SUD) and anaesthesia 195–216
basic aspects of SUD 195–199
clinical aspects of SUD 200
CNS-depressants 200–206
alcohol 204
barbiturates 206
benzodiazepines 206
fuels and solvents 205
heroin and other opioids 200–204
volatile nitrates 205
CNS-stimulants 206–207
amphetamines 206
cannabis (marijuana) 207
cocaine 206
lysergic acid diethylamine (LSD) 207
phencyclidine 207
definitions 199
physical dependence 199
terminology 215–216
tolerance 199
drug-free recovery 207–210
anaesthesia 208
analgesia 208–209
sulphonylurea, blockade of potassium voltage-gated channel 85
sulphonylurea receptor 20
synteny 21
terfenadine 16
thiazolidinone 17
thiopurine S-methyl transferase (TPMT), phase-II metabolism 14–15
thoracic aorta, traumatic rupture 107
thrombin 58–61, 151–152
prothrombin time 61–2
thrombin-activated fibrinolysis inhibitor 60
thrombomodulin 58, 151–152
thrombotic disorders 66–7
deep venous thrombosis 123
prothrombotic traits 66
thromboxane 56
tissue factor (TF) 56–8, 69
tissue factor pathway inhibitor (TFPI) 57–8, 61
torsade-de-pointes 19
toxicogenomics, defined 23
tracheal wounds 106
tramadol, CYP2D6 phase-I metabolism 4, 8–9
transcranial Doppler, blunt chest trauma 114–115
trauma altered glucose regulation 177–178
see also chest trauma troponin 116
ultrasound abdominal sonography 114 chest trauma 110–111 pleural 112–113 ultrasound-guided vascular access 115
Valsava manoeuvre, square wave 138 vancomycin 166 variable number tandem repeats (VNTRs) 4–5
ventilation mechanical 121–122 non-invasive, heart failure 97 volatile anaesthetic agents, CYP2E1 phase-I metabolism 13 volatile fuels and solvents 205 von Willebrand disease 63–4 acquired 70 von Willebrand factor (vWF) 56–9
warfarin CYP2C9 phase-I metabolism 9–12 reversal 70 whole-body CT scanning associated abdominal injury 118 blunt aortic injury 117–118 lung contusion 117 spinal injury 118 xenobiotics 3